Literature DB >> 24861225

[Psychosis as debut of antiphospholipid syndrome].

Lucía del Rio-Casanova1, Eduardo Paz-Silva, Ignacio Requena-Caballero, Francisco Diaz-Llenderrozas, Jesús Gomez-Trigo Baldominos, Alberto de la Cruz-Davila, Mario Paramo-Fernandez.   

Abstract

INTRODUCTION: Antiphospholipid syndrome (APS) is an autoimmune disorder which causes an hypercoagulation state characterized by thrombotic events, repetitive miscarriages and the presence of antiphospholipid antibodies. APS may be an isolated disease (primary APS) or associated to systemic lupus erythematous or another autoimmune conditions (secondary APS). Neuropsychiatric manifestations accompanying APS include migraine, epilepsy, chorea, dementia or psychosis. Detailed descriptions of clinical cases are lacking, and correlations between clinical and analytical findings are far from being well known. We review literature concerning neuropsychiatric manifestations in general and psychosis in particular, in patients suffering from AFS. CASE REPORT: A 23 years-old female who presented a primary AFS with a clinical debut consisting of neuropsychiatric manifestations characterized by psychosis (with two delusion episodes) and abnormal movements such as choreiform and hemiballistic movements, initially understood as conversive symptoms.
CONCLUSIONS: We discuss the pathogenesis of the psychotic and motor manifestations. The etiology is nowadays not completely understood, but cerebral small vessel thrombosis might explain part of the manifestations. We also review the role of antipsychotic and antithrombotic medication for these patients. Currently, our patient remains asymptomatic without any antipsychotic agent, only being treated with antiagregant and antipalludic therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24861225

Source DB:  PubMed          Journal:  Rev Neurol        ISSN: 0210-0010            Impact factor:   0.870


  1 in total

Review 1.  Anti-phospholipid syndrome associated with schizophrenia description of five patients and review of the literature.

Authors:  Pikman Regina; Rotman Pnina; Aiman Natur; Levy Yair
Journal:  Immunol Res       Date:  2017-04       Impact factor: 2.829

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.